摘要
肝癌术后的高复发及转移率仍然是阻碍着患者生存的障碍,降低复发是改善肝切除术后预后的关键。针对肝癌术后存在高复发和转移风险,目前尚无预防和治疗的标准方案。本文讨论了可能降低肝癌术后复发风险并提高生存率的辅助治疗方案的进展,包括肝动脉化疗栓塞、分子靶向药物和免疫疗法的辅助全身治疗、抗病毒和其它局部治疗以及潜在的联合治疗。选择具有个性化的联合治疗模式可能是防治HCC术后复发的发展趋势,但这仍需要进一步验证。
The high recurrence rate and metastasis of hepatocellular carcinoma(HCC)after surgery still hinders the improvement of patients′survival.Reducing the recurrence rate after hepatectomy is the key prolonging the recurrence⁃free survival and reducing extrahepatic recurrence.For patients with high risk of recurrence after surgery,there is no standard therapy procedure to prevent recurrence after radical resection of HCC.This article discusses the progress of adjuvant therapy that may reduce the risks of recurrence and improve the survival rate after hepatectomy,including transcatheter arterial chemoemboli⁃zation(TACE),molecular targeted therapy and adjuvant immunotherapy,antiviral and other local thera⁃pies,and combination therapy.The paradigm with selective personalized combination therapy may be the development trend of prevention and treatment of postoperative recurrence of HCC,but this still needs further research for verification.
作者
管玉婷
曾国斌
陈建平
吴雄健
GUAN Yu-ting;ZENG Guo-bin;CHEN Jian-ping;WU Xiong-jian(Gannan Medical University,Ganzhou,Jiangxi 341000,China;Department of Interventional Radiol-ogy,Meizhou People′s Hospital,Guangdong 514031,China;Department of Gastroenterology,First Affiliated Hospital of Gannan Medical University,Ganzhou,Jiangxi 341001,China)
出处
《岭南现代临床外科》
2023年第2期193-199,共7页
Lingnan Modern Clinics in Surgery
基金
梅州市科技计划项目(2022B35)
梅州市人民医院培育项目(PY-C2022012)。
关键词
肝细胞癌
复发
辅助治疗
TACE
免疫治疗
化疗
靶向治疗
hepatocellular carcinoma
currrence
adjuvant therapy,TACE
immunotherapy,che⁃motherapy,targeted therapy
